Roth's Piros: Galectin Therapeutics Shares Can Quadruple In Next 12 Months

Shares of Galectin Therapeutics Inc GALT could reach $6 in the next twelve months, according to Roth Capital's Elemer Piros who initiated the stock with a Buy rating. Galectin is developing a drug that could prevent and reverse fibrosis in nonalcoholic steatohepatitis (NASH) patients who suffer from cirrhosis. There are only a handful of drugs in mid-stage development. Galectin's GR-MD-02 has a differentiated profile: it can reduce inflammation and prevent and reverse fibrosis in animal models. "There are ~50MM patients suffering from NASH in the U.S. and in key European countries (EU5), in our estimate," Piros wrote in a note to clients. The path for drug approval for NASH is evolving. Intercept Pharmaceuticals Inc ICPT and Genfit GNFTF, with Phase 3 drug candidates, are paving the way with regulators. By the time Galectin gets to the pivotal stage (2018), the market will have a much better understanding of trial endpoints, duration and patient characteristics. "While their drugs may reduce inflammation and liver fat, we are unimpressed with the results on decreasing fibrosis. As a matter of fact, to our knowledge Galectin's GR-MD-02 is the only drug candidate to prevent and reverse progression of fibrosis," Piros noted. Galectin plans to release data on GR-MD-02's impact on fibrosis in NASH patients, using non-invasive imaging, as an endpoint. The findings are expected to be out in the third quarter of 2016. While the study is small (15+15 patients), GR-MD-02 could be the first agent to show an effect on fibrosis in four months, where others failed to impress even after 72 weeks of treatment. A much larger trial (50+50+50 patients) investigates GR-MD-02 in advanced NASH cirrhosis, with a potential readout in the fourth quarter of 2017. Piros said NASH is a multibillion-dollar indication. The bar set by Intercept and Genfit is relatively low: 10-15 percent meaningful response rates are observed. The impact on fibrosis is questionable at best. During the next six-to-20 months, it will be known whether GR-MD-02's favorable preclinical profile translates to success in patients. "In our calculation, GR-MD-02 could achieve ~$7B in peak sales five years from launch (2022) in 2026. We estimate the risk-adjusted NPV (25% probability of success, 15% discount rate) of a royalty stream (20%) at $285MM, or $6/fully diluted share, corresponding to our 12-month target price of $6/share on Galectin," Piros added. Shares of GALT were down 3.35 percent at $1.44. They have dropped 11.58 percent this year.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorNewsPrice TargetInitiationAnalyst Ratings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!